ArticleLife (Basel, Switzerland)2022
Ex-Vivo Preservation with the Organ Care System in High Risk Heart Transplantation.
Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Resveratrol-loaded chitosan nanoparticles and adipose-derived stem cell-conditioned medium for liver protection against ischemia-reperfusion injury.Journal of materials science. Materials in medicine · 2026Article
- Comparative analysis of bypass vs. stent for coronary revascularization using an ex-vivo organ care system in an animal model.Scientific reports · 2026Article
- Beating heart technique for orthotopic heart transplantation after ex vivo heart perfusion: Clinical application and experience.JTCVS techniques · 2026Article
- New Perfusion and Preservation Strategies for Donor Hearts.European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes · 2026Review
- Article
- Microplastic in perfusion: the hidden risk and how to address it.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Introduction of ex vivo perfusion of extended-criteria donor hearts in a single center in Asia.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Article
- Clinical Outcomes of Machine Perfusion and Temperature Control Systems in Heart Transplantation: Where We Stand.Journal of clinical medicine · 2025Review
- Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Review
- Donor Heart Recovery and Preservation Modalities in 2024.JACC. Heart failure · 2024Review
- [Heart transplantation : Current situation].Chirurgie (Heidelberg, Germany) · 2024Review
- Donor Heart Preservation: Current Knowledge and the New Era of Machine Perfusion.International journal of molecular sciences · 2023Review
- Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States.Transplantation direct · 2023Article
- Thoracic organ machine perfusion: A review of concepts with a focus on reconditioning therapies.Frontiers in transplantation · 2023Review
- Graft preservation in heart transplantation: current approaches.Frontiers in cardiovascular medicine · 2023Review
- Strategies for Expanding Donors Pool in Heart Transplantation.Reviews in cardiovascular medicine · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEx vivo organ perfusion is an advanced preservation technique that allows graft assessment and extended ex situ intervals. We hypothesized that its properties might be especially beneficial for high-risk recipients and/or donors with extended criteria.
methodsWe reviewed the outcomes of 119 consecutive heart transplant patients, which were divided into two groups: A (OCS) vs. B (conventional). Ex vivo organ perfusion was performed using the Organ Care System (OCS). Indications for OCS-usage were expected ischemic time of >4 h or >2 h plus given extended donor criteria.
resultsBoth groups included mostly redo cases (A: 89.7% vs. B: 78.4%;
conclusionsOCS heart allowed safe transplantation of surgically complex recipients with excellent one-year outcomes, despite long preservation times and unfavourable donor characteristics. Furthermore, we observed trends towards decreased ventilation times and fewer ECLS treatments. In times of reduced organ availability and increasing recipient complexity, OCS heart is a valuable instrument that enables otherwise infeasible allocations and contributes to increase surgical safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.